Amit Varma, managing partner and co-founder of the company, said in a statement: "The Asian health care sector is at a critical turning point, and this industry will be the focus this year, especially driven by investment interest in India."
Singaporean private equity investment company Quadria Capital raised US$1 billion (about S$1.373 billion) for its third investment fund, surpassing the original US$800 million target.
Thecompany noted that it will use funds to build a diversified portfolio of about 10 leading market companies. Nearly 40% of the funds have been invested in Aragen Life Sciences, blood purification chain NephroPlus, and ophthalmic care chain Maxivision. The company also plans to make two new investments in Southeast Asia.
This round of financing was oversubscribed, of which more than US$954 million was the core investment commitment; US$114 million was the co-investment commitment; and US$300 million was the co-investment expected to be invested in the investment stage.
The company revealed that the funds raised this time are about 60% more than the $600 million raised in 2020, allowing the company to hold the largest healthcare private equity funds in South and Southeast Asia.
Quadria Capital made the above announcement Tuesday (May 27). Existing investors involved in this round include sovereign wealth funds, asset management companies, and strategic enterprises in North America and Europe. The new investors are the Gulf Arab States Cooperation Council (Gulf Cooperation Council, referred to as GCC), as well as some Indian and influential investors.